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The A1555G mitochondrial mutation is the main alteration 
associated with aminoglycoside-induced deafness. Aim: 
to investigate the prevalence of the A1555G mutation in 
patients sensorineural hearing loss patients with and without 
aminoglycosides antibiotic use. Material and Method: a study 
of 27 cases with deafness as the sample, and 100 neonates 
with normal hearing as the control group. DNA was extracted 
from blood leukocyte samples, and specific oligonucleotide 
primers were designed to amplify the cytochrome b gene 
and the region which encloses the A1555G mutation of the 
mitocondrial DNA using the polymerase chain reaction and 
restriction fragment length polymorphism. Design: a cross-
sectional case study. Results: a region of the cytochrome 
b gene was amplified and the presence of the mtDNA was 
confirmed in all of the 127 cases. The A1555G mutation was 
not found in any of the 27 patients with hearing loss or the 
control group with 100 neonates. Conclusion: the results 
agree with studies stating that the A1555G mutation is not 
prevalent in the Americas. There is interest in establishing 
the real prevalence of this mutation and to investigate other 
mutations that may cause hearing loss, associated or not with 
the use of aminoglycosides, in the Brazilian population.
Keywords: aminoglycosides, hearing loss, mitochondrial 
DNA, mutation.
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INTRODUCTION
It is estimated that in developed countries, one child 
in 750 births presents sensorineural hearing loss, and that 
one child in each 1,000 births becomes deaf before adul-
thood. The prevalence increases further and reaches 50% 
in octogenarians.1 About 60% of all causes of prelingual 
hearing loss may be attributed to hereditary factors. Thus, 
inheritance is becoming more and more relevant in hearing 
loss and/or deafness. The remaining 40% are caused by 
various etiologies.2 There are three identifiable possible 
inheritance patterns in hereditary hearing loss: autosomal 
recessive, autosomal dominant and X-linked. About 75% 
to 85% of non-syndromic prelingual hearing loss cases 
manifest as autosomal recessive conditions. Autosomal 
dominant forms respond for about 15% to 25% of cases; 
the remaining 1% to 3% cases are Mendelian inheritance 
X-linked conditions. There are forms inherited exclusively 
from the mother - mitochondrial inheritance - in about 
0.5% to 1% of sensorineural hearing loss of genetic causes; 
spontaneous mutation may also occur.2,3 A relation betwe-
en mitochondrial disease and hearing loss was established 
in 1986 based on the study of a patient with mitochondrial 
myopathy and hearing loss.4
Mitochondrial mutations, especially those in the 
12S rRNA and tRNASer(UCN) genes, are important causes 
of non-syndromic sensorineural hearing loss in some po-
pulation groups.5 Among these mutations, a substitution 
of A->G nitrogenated bases in position 1555 of the mito-
chondrial DNA 12S rRNA gene is or particular interest as 
the main cause of aminoglycoside-induced hearing loss. 
It was identified in 1993 by a study that described it as a 
mitochondrial rRNA mutation that led to non-syndromic 
hearing loss; this was the first molecular genetic analysis 
of aminoglycoside-induced ototoxicity.6
Many studies have suggested that the A1555G mu-
tation by nitrogenated base substitution generates a new 
pair of C-G bases, making the secondary structure of the 
human 12S rRNA gene strictly similar to the corresponding 
region of the E. coli 16S rRNA gene; this is referred to 
as the decoding bacterial rRNA region and an important 
action site for aminoglycosides.6,7 Aminoglycoside binding 
to the decoding region results in protein translation errors 
and ensuing bacterial death. When there is a generally 
homoplasmic mutation altering the human 12S rRNA gene, 
making its structure similar to that of the bacterial rRNA, 
aminoglycosides concomitantly bind to cochlear cell mito-
chondrial DNA, which potentializes its toxic effect in the 
inner ear, resulting in hearing loss. These studies, therefore, 
demonstrate the highly specific recognition mode among 
RNA molecules and aminoglycosides.7
In contrast with systemic mitochondrial mutations, 
which usually affect only a fraction of all mitochondrial 
DNA molecules (heteroplasmia), mutations associated with 
non-syndromic sensorineural hearing loss are generally 
homoplasmic, and phenotypes may differ considerably 
among members of the same family, ranging from deep 
hearing loss to normal hearing. Many factors, such as nu-
clear genes, mitochondrial DNA haplotypes, environmental 
factors or tissue-specific factors, may operate independen-
tly or in association, and may alter the clinical expression. 
However, research has not found nuclear modifying genes 
or correlations among mutations and mitochondrial haplo-
types. The only known environmental factors affecting the 
A1555G mutation are the aminoglycosides.8
Although mitochondrial mutations are etiologically 
relevant in sensorineural hearing loss, few studies have 
been made in developing countries, especially in Brazil. 
The purpose of this study, therefore, was to investigate 
the prevalence of the mitochondrial A1555G mutation in 
patients with non-syndromic sensorineural hearing loss 
with and with no exposure to aminoglycosides.
SERIES AND METHOD
A cross-sectional study was made between Septem-
ber and October 2006 of 20 index cases of non-syndromic 
sensorineural hearing loss (12 males and 8 females) aged 
from 1 to 37 years, previously submitted to GJB2 gene 
and D(GJB6-D13S1830) mutation molecular analysis; the 
cases had no molecular changes.9 The index cases in our 
sample consisted of 16 sporadic cases (single cases within 
a family) and four familiar cases (familiar cases). Relati-
ves with hearing loss were also assessed (2 males and 5 
females) aged from 5 to 45 years. Thus, 27 hearing loss 
patients were studied.
A complete history was taken from each patient to 
investigate the age of onset of hearing loss, other cases 
in the family, the use of ototoxic drugs (aminoglycosi-
des), and to exclude other environmental causes such 
as maternal-fetal infections, perinatal complications, me-
ningitis, acoustic trauma and consanguineous marriages. 
Patients underwent a physical examination (systemic and 
otorhinolaryngological) and laboratory exams, to exclude 
syndromic forms of hearing loss (especially craniofacial 
dimorphism, skin alterations, and branchial, heart and 
thyroid anomalies, vision disorders, etc.). Other tests were 
an ophthalmologic evaluation (including fundoscopy), 
vestibular tests, and temporal bone computed tomogra-
phy. Thus, a complete clinical assessment was made to 
exclude patients with hearing loss due to environmental 
factors except for aminoglycoside use, consanguinity, con-
genital inner ear malformations and genetic syndromes. 
Audiological testing consisted of pure tone audiometry, 
based on which patients with non-syndromic sensorineural 
hearing loss were included in the study and classified as 
mild (25-40 dB), moderate (41-60 dB), severe (61-80 dB) 
or profound (>81 dB).10
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The patients in the sample were identified as the 
Hearing Loss Group (HLG) and divided into two sub-
groups:
. HLG group I - patients that used aminoglycosides 
(n=13).
. HLG group II - patients that did not use amino-
glycosides (n=14).
One hundred term neonates with one-minute Apgar 
scores ≥7 and normal otoacoustic emissions tests (done 
within three days of birth) were selected as the control 
group (CG).
The Research Ethics Committee of our institution 
approved this study (protocol nº 2784/2006). Parents or 
legal caretakers read and signed a free informed consent 
form, after which 4.0 ml of whole blood (from a peripheral 
vein in the HLG group and from the umbilical cord after 
its ligature in the control group) was taken and placed 
on a VacutainerÒ tube containing anticoagulant (EDTA). 
Genomic DNA was extracted from the blood samples of 
both groups using the GFXTM Genomic Blood DNA Puri-
fication Kit (Amersham Pharmacia Biotech Inc.) according 
to the manufacturer’s instructions. Mitochondrial DNA 
fragments including the mutation region were amplified 
using the polymerase chain reaction (PCR) technique 
in a thermocycler (Applied Biosystems - GeneAmp PCR 
System 9700Ò) to detect the A1555G mutation.11 A pair of 
primers were synthesized for this reaction and were used 
to incorporate the deoxynucleotide triphosphates (dNTPs) 
to initiate DNA amplification, respecting base complemen-
tarity (A-T/C-G); mitochondrial DNA was then amplified. 
Oligonucleotide primer sequences and the conditions for 
the PCR were in accordance with the literature.11
A 643 bp fragment was amplified as a PCR product 
and then submitted to restriction fragment length polymor-
phism (RFLP) analysis, using the BsmAI11 enzyme (New 
England Biolabs)Ò during two hours at 55ºC. Enzymatic 
digestion of normal A1555G mutation sample fragments 
yields two fragments (413 bp and 230 bp) as a results of 
BsmAI enzyme restriction site recognition. Mutation sam-
ples yield only the 643 bp fragment, as there is no enzyme 
site recognition, due to substitution of A->G nitrogenated 
bases in position 1555 of the mitochondrial DNA.
A second primer pair was also synthesized to ampli-
fy a specific cytochrome b region.12 This specific region - a 
highly conserved area of the mitochondrial genome - is 
used as an internal amplification control to verify the pre-
sence of mitochondrial DNA in the samples. The expected 
size of PCR-amplified fragments using the CitbF and CitbR 
primers was 161 bp. Oligonucleotide primer sequences 
and the conditions for PCR were in accordance with the 
literature.12
Both primer pairs used in the PCR include regions 
in the “Human Mitochondrial DNA Revised Cambridge 
Reference Sequence.”13
The products of both reactions (PCR and RFLP) 
were analyzed using 2% agarose gel electrophoresis in a 
TBE 1X buffer containing ethidium bromide, at 0.5mg/mL 
concentration, submitted to ultraviolet light, to confirm the 
success of the reaction and gel; photographic documen-
tation was done.
Statistical analysis:
A pilot study was done to assess 100 newborns to 
estimate the proportion (p) of probable A1555G mutation 
carriers in the initial sample. The statistical formula “sam-
ple size with a known population” was applied to the 
proportion (p) to obtain the final sample size (n) needed 
for statistically representing the total population (Np) of 
newborns born within the study period (Np=352 neonates). 
The final sample (n) was calculated using the abovemen-
tioned statistical formula with the following parameters: 
p=0.00 (estimated by the pilot sample); q=1.00; zc=3.00 
(99.74% reliability); e=0.03 (3% estimated error); Np=352 
(population size within the study period).
Formula: n = zc2 × p × q × N
p
e2 × (Np - 1) zc2 × p × q
Results were expressed as percentages.
RESULTS
PCR was done for amplification of the b cytochrome 
gene region to visualize the corresponding 161 bp fragment 
to confirm the presence of mitochondrial DNA in all 127 
samples of the study - 100% (HLG I and II groups - n=27 
and the control group - n=100).
PCR enabled amplification of the mitochondrial 
DNA 643 bp fragment encompassing the mutation area in 
all of the samples (100%) of HLG I and II groups (n=27) 
and the control group (n=100).
The A1555G mitochondrial mutation was not found 
in the study sample (100%); 413 bp and 230 bp fragments 
were found after enzymatic digestion, which were am-
plified in the absence of mutation in all samples within 
both groups (HLG I and II groups - n=27 and the control 
group - n=100).
Clinical and audiometric data from the index cases, 
such as sex, age, onset and degree of hearing loss, use of 
aminoglycosides and family cases are shown in Chart 1.
DISCUSSION
Research in population groups in various European 
countries has found that conexin 26 (Cx26) gene mutations 
may cause hearing loss in a significant proportion of ca-
ses. Continued research has led to the discovery of other 
mutations, which has made possible molecular etiological 
identification in many patients; thus, early rehabilitation 
and genetic counseling have become feasible in these 
cases. It is interesting to note that the frequency of genes 
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and mutations that cause hearing loss varies significantly 
among populations. The 35delG mutation in the Cx26 
gene, for example, is highly prevalent among deaf persons 
of European descent,9,14 and almost absent in Japanese, 
Korean or Mongolian individuals.15,16
Similarly, the frequency of mitochondrial mutations 
also differs among populations; the A1555G mutation is 
found mostly in patients with maternally inherited hea-
ring loss, although it has been sporadically identified in 
patients with hereditary autosomal recessive conditions. 
There are major differences in ethnic origin in both trans-
mission modes, as revealed by recent studies showing 
the mutation to be a frequent cause of non-syndromic 
hearing loss, associated or not with aminoglycoside use, 
in Asian,11,17-21 Arab,22 and South African23 populations. It 
is, however, rare in most of the European and American 
populations.24,25 
A study in 32 Asians with hearing loss and in 100 
American controls (63 deaf and 37 normal-hearing) found 
the A1555G mutation in 87.5% of Asians that were deaf, 
and in none of the subjects in the control group, con-
cluding that the mutation is not prevalent in non-Asian 
populations.25 This results has been confirmed in a study 
done in Greece, in which the mutation was absent in 106 
cases,26 and in another study involving 202 early onset 
non-syndromic hearing loss patients in the United King-
dom.5 Likewise in our study, the A1555G mitochondrial 
mutation was not found in the HLG groups (consisting of 
group I: 13 index cases that had taken aminoglycosides, 
and group II: 14 index cases that had no prior use of 
aminoglycosides) and in the control group (100 neonates 
with normal otoacoustic emissions tests). These results 
demonstrate that the mutation was not a common cause 
of hearing loss in our sample.
Two mutation screening program have been done 
in neonates in the USA. The first of these sampled um-
bilical cord blood of 1,773 neonates, of which only one 
carried the mutation.27 The second screened 25 neonates 
that had altered otoacoustic emissions tests, among which 
the mutation was not found.28 Screening of 300 neonates 
in Argentina and in 712 normal-hearing subjects did not 
detect the A1555G mutation.29 These studies have reported 
Chart 1. Clinical and audiometric data of the 20 index cases in the sample and the 7 affected family members (n=27) that underwent molecu-
lar analysis for the detection of the A1555G mitochondrial mutation.
Index case
(IC)
Sex
Age
(Years) 
Onset of
HL
Degree of
HL
Use of AMG 
Family 
Cases
Age
(Years)
Degree of
HL
Use of AMG
1 F 12 Prelingual Profound No
2 M 9 Prelingual Severe Yes
3 F 28 Postlingual Profound No
4 F 3 Prelingual Profound Yes
5 M 8 Prelingual Severe Yes
6 M 4 Prelingual Profound Yes
7 F 10 Postlingual Severe Yes
8 M 7 Prelingual Profound Yes
9 M 3 Prelingual Severe Yes
10 F 3 Prelingual Profound Yes
11 M 9 Prelingual Profound Yes
12 M 5 Prelingual Profound Yes
13 F 33 Prelingual Severe No
sister - 14
brother - 15
brother - 16
28
37
19
Moderate
Profound
Profound
No
No
No
17 M 37 Postlingual Profound No
18 F 5 Prelingual Profound Yes
19 M 10 Prelingual Moderate No mother - 20 38 Moderate No
21 M 8 Prelingual Severe Yes
22 M 7 Prelingual Profound No mother - 23 45 Moderate No
24 M 32 Prelingual Profound Yes
25 F 10 Prelingual Profound No
sister - 26
sister - 27
8
5
Severe
Severe
No
No
(IC)- Index cases; (M)- Male; (F)- Female; (HL)- Hearing Loss
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low rates in North-American populations, but have not 
discarded the need for molecular studies in neonatal scre-
ening tests, especially in countries where aminoglycosides 
are used routinely.
Our method has already been described in the 
literature;11 it includes amplifying a specific cytochrome 
b gene region - a highly conserved mitochondrial genome 
area - to serve as an amplification control for identifying 
mitochondrial DNA in all of the samples.12 Although the 
number of cases in both groups was different from the 
number in some published studies, and although the mu-
tation was not found in both groups (HLG and control 
groups), we were able to confirm the results of studies 
that also did not find the mutation in non-Asian or Arab 
ethnic groups.24-29
There is a single study in Brazil reporting the fin-
dings of five families with hearing loss cases in which the 
prevalence of the mutation was 2% (4 cases). Only one 
of these positive cases was associated with an assumed 
aminoglycoside exposure; no mutation was found in the 
control group composed by black, white or Asian (Japa-
nese or Chinese) ethnic groups.30 These results - which are 
different from our study - may be explained by the highly 
heterogeneous ethnic composition of the Brazilian popu-
lation that resulted from racial mixing; this may explain 
prevalence variations in different Brazilian regions.
Many mutations may result in hearing loss; the 
A1555G mitochondrial mutation, which is related to amino-
glycoside use, may be only one of them.17,30 Understanding 
the underlying causes of hearing loss caused by amino-
glycoside exposure is essential for therapy - especially 
in neonatal ICUs - and for genetic counseling and early 
rehabilitation. This is necessary for including or returning 
these patients to their social and professional activities.
CONCLUSION
The PCR/RFLP molecular techniques, such as the 
protocol we used in this study, are simple methods for 
tracking the A1555G mutation, supporting the molecular 
investigation of hearing loss.
There has been considerable interest in establishing 
the true prevalence of the A1555G mitochondrial mutation 
in the Brazilian population by means of molecular testing, 
as well as investigating other mutations that may result in 
hearing loss associated or not with aminoglycoside use. 
These tests may become a valuable adjunct for neonatal 
audiometric screening.
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